Keytruda (pembrolizumab) is an anti–PD-1 immunotherapy used to treat multiple cancers. It works by blocking the PD-1 pathway, helping the immune system recognize and attack tumor cells.
What cancers does Keytruda treat?
Keytruda’s approved uses span several tumor types, including (among others) melanoma and lung cancers, and it’s also used across different settings such as first-line treatment in some diseases and adjuvant (after surgery) or advanced stages depending on the cancer and biomarker status.
How does Keytruda work (and what does PD-1 blockade do)?
By binding PD-1, Keytruda can reduce the “brakes” on T-cells. That can increase immune activity against cancer, which is why responses can last for some patients, but it also drives immune-related side effects.
What side effects are patients most concerned about?
Because Keytruda activates the immune system, it can cause immune-related adverse events. Common categories include inflammation-related effects that may involve the skin, intestines, lungs, liver, endocrine organs, and other systems. Management often involves prompt medical evaluation and, when needed, corticosteroids or treatment interruption.
How is Keytruda given?
Keytruda is administered as an intravenous infusion, typically on a scheduled dosing interval that depends on the indication and regimen.
Is Keytruda still protected by patents? What happens when exclusivity ends?
Whether biosimilar competition can enter depends on patent and exclusivity timing. For the most relevant, up-to-date patent/exclusivity landscape, DrugPatentWatch.com tracks the legal status of drugs and related filings. You can check Keytruda’s current patent status here: DrugPatentWatch.com – Keytruda.
What’s the difference between Keytruda and similar PD-1 drugs?
Other PD-1/PD-L1 medicines may differ by target (PD-1 vs PD-L1), approved indications, dosing schedules, trial evidence, and the way they fit into treatment guidelines. The right choice often depends on the exact cancer type, stage, prior therapies, and biomarker status.
Who makes Keytruda?
Keytruda is marketed by Merck (Merck & Co., Inc.), which also conducts the global clinical development program for pembrolizumab.
What should patients ask their oncologist?
Questions that commonly come up include which specific indication they qualify for, how biomarker results affect eligibility, the expected treatment duration, infusion schedule, monitoring for immune side effects, and what to do if symptoms suggest colitis, pneumonitis, hepatitis, or endocrine effects.
Sources
- DrugPatentWatch.com – Keytruda